ASBP

Aspire Biopharma Holdings, Inc. (ASBP) PESTLE Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Overall Score

Score: 5.0 (Moderate)

Political

Score:

No major political or regulatory catalyst is evident from the current data.

ASBP remains a micro-cap with limited disclosed operating scale, which can increase sensitivity to policy or reimbursement changes.

Economic

Score:

Liquidity appears strong with a current ratio of 7.99 and cash ratio of 7.22, supporting near-term resilience.

However, profitability remains deeply negative on a TTM basis, with net profit margin at -113.14% and operating cash flow ratio at -4.26.

Social

Score:

No new social or demand-shift news was provided this month.

The company’s very small revenue base and micro-cap profile imply limited evidence of broad market adoption.

Technological

Score:

R&D spending is present at 8.58% of revenue, indicating ongoing product development effort.

There is no fresh news indicating a material technology breakthrough or pipeline acceleration.

Legal

Score:

No new litigation, compliance, or legal developments were reported this month.

The absence of debt reduces some covenant-related legal risk, but operating losses keep financing risk elevated.

Environmental

Score:

No material environmental disclosures or ESG-related news were provided.

With no fresh operational updates, environmental impact remains difficult to assess from the available data.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →